SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities
Arturo Casadevall, Jeffrey P. Henderson, Michael J. Joyner, Liise‐anne Pirofski
Abstract
In recent months genomic characterization of pandemic SARS-CoV-2 isolates identified viral variants that are less susceptible to neutralization by convalescent plasma (CP), vaccine-elicited plasma/sera, or SARS-CoV-2 monoclonal antibodies than earlier SARS-CoV-2 strains. In this Viewpoint, Casadevall et al. argue against the causal association made in some press articles between the emergence of SARS-CoV-2 variants and convalescent plasma use.
Topics & Concepts
Convalescent plasmaSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)VirologyCoronavirus disease 2019 (COVID-19)Monoclonal antibody2019-20 coronavirus outbreakPandemicNeutralizationAntibodyBiologyImmunologyMedicineVirusOutbreakInternal medicineInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesVaccine Coverage and Hesitancy